主要文件

查看所有文档

A0773

血管紧张素转换酶抑制剂

Name: 血管紧张素转换酶抑制剂
Brand: SIGMA

≥95% (TLC)

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₅₃H₇₆N₁₄O₁₂

化学文摘社编号:

35115-60-7

分子量:

1101.26

NACRES:

NA.77

PubChem Substance ID:

329770629

UNSPSC Code:

12352200

MDL number:

MFCD00076208

Assay:

≥95% (TLC)

Form:

powder

Quality level:

200

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

biological source

synthetic (organic)

Quality Level

200

assay

≥95% (TLC)

form

powder

mol wt

~_1.1 kDa

solubility

water: soluble 1 mg/mL, clear, colorless

storage temp.

−20°C

SMILES string

CC[C@H](C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H]2CCCN2C(=O)[C@H](Cc3c[nH]c4ccccc34)NC(=O)[C@@H]5CCC(=O)N5)C(=O)N6CCC[C@H]6C(=O)N7CCC[C@H]7C(O)=O

InChI

1S/C53H76N14O12/c1-3-29(2)43(51(77)66-25-9-16-39(66)50(76)67-26-10-17-40(67)52(78)79)63-45(71)34(18-20-41(54)68)60-46(72)37-14-7-23-64(37)48(74)35(13-6-22-57-53(55)56)61-47(73)38-15-8-24-65(38)49(75)36(62-44(70)33-19-21-42(69)59-33)27-30-28-58-32-12-5-4-11-31(30)32/h4-5,11-12,28-29,33-40,43,58H,3,6-10,13-27H2,1-2H3,(H2,54,68)(H,59,69)(H,60,72)(H,61,73)(H,62,70)(H,63,71)(H,78,79)(H4,55,56,57)/t29-,33-,34-,35-,36-,37-,38-,39-,40-,43-/m0/s1

InChI key

UUUHXMGGBIUAPW-CSCXCSGISA-N

说明

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

法规信息

常规特殊物品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

The metabolism of neuropeptides. The hydrolysis of peptides, including enkephalins, tachykinins and their analogues, by endopeptidase-24.11.

R Matsas et al.

The Biochemical journal, 223(2), 433-440 (1984-10-15)

Endopeptidase-24.11 (EC 3.4.24.11), purified to homogeneity from pig kidney, was shown to hydrolyse a wide range of neuropeptides, including enkephalins, tachykinins, bradykinin, neurotensin, luliberin and cholecystokinin. The sites of hydrolysis of peptides were identified, indicating that the primary specificity is

Activation of glutathione peroxidase and inhibition of p53-related apoptosis by apomorphine.

Linqing Ma et al.

Journal of Alzheimer's disease : JAD, 27(1), 225-237 (2011-07-30)

Apomorphine hydrochloride (APO) is known to be a dopamine receptor agonist, and has recently been found to be a novel drug for Alzheimer's disease (AD). We found that APO treatment ameliorated oxidative stress in an AD mouse model and specifically

A new perspective on therapeutic inhibition of advanced glycation in diabetic microvascular complications: common downstream endpoints achieved through disparate therapeutic approaches?

Karly C Sourris et al.

American journal of nephrology, 30(4), 323-335 (2009-06-27)

A commonality among the chemically disparate compounds that inhibit the formation and accumulation of advanced glycation end products (AGEs) or their signalling pathways is their end organ protection in experimental models of diabetes complications. Although this group of therapeutics are

查看所有相关文献

全球贸易项目编号

货号	GTIN
A0773-1MG	04061833334386
A0773-.5MG	04061834885764
A0773-5MG	04061832895574

主要文件

血管紧张素转换酶抑制剂

≥95% (TLC)

选择尺寸

关于此项目

biological source

Quality Level

assay

form

mol wt

solubility

storage temp.

SMILES string

InChI

InChI key

安全信息

存储类别

wgk

flash_point_f

flash_point_c

ppe

法规信息

文件

分析证书(COA)

已有该产品？

同行评审论文

全球贸易项目编号